Name: 글로벌 시장 동향
SKU: PH1511
Availability: InStock

보고서 요약(국문)

항균제 시장 개요
전 세계 항균제 시장은 2022년 438억 5,740만 달러에 달했으며, 2030년까지 633억 2,680만 달러에 이르러 높은 성장세를 보일 것으로 예상됩니다. 전 세계 항균제 시장은 예측 기간(2023~2030년) 동안 연평균 4.8%의 성장률을 기록할 것으로 전망됩니다.
최근 시판되었거나 FDA 승인을 기다리고 있는 항균제들이 전 세계 항균제 시장의 주요 트렌드 중 하나입니다. 새로운 표적을 가진 많은 신약들이 최근 시판되었으며, 일부는 FDA 승인을 기다리고 있습니다. 이러한 신약에는 거대고리 항생제, 새로운 세팔로스포린, 새로운 글리코펩타이드, 새로운 카바페넴, 플레우로뮤틸린 등이 포함됩니다.
항균제는 일반적으로 항생제로 알려져 있으며, 세균 감염 치료에 사용되는 약물입니다. 항생제는 특정 세균이나 세균의 활동(예: 세포벽 또는 단백질 합성)을 표적으로 합니다. 정확한 치료법과 용량은 질병의 종류와 심각도에 따라 달라집니다. 항균제는 경구, 국소, 정맥 주사 등 다양한 방식으로 투여할 수 있습니다.
또한 만성 질환 발생률 증가, 임상 시험 증가, FDA 승인 건수 증가, 항균제 연구 확대 등이 향후 시장 성장을 견인할 것으로 예상됩니다.
항균제 시장 동향 및 추세
시장 개발 건수 증가는 전 세계 항균제 시장 성장을 촉진하고 있습니다.
다제내성 그람 음성균(MDR-GNB)의 위협이 커짐에 따라 전 세계적으로 항균제 개발의 시급성이 높아지고 있습니다. 제약 회사들은 연구 개발 비용을 절감하고 신약 개발을 장려하는 향후 규제 개선의 혜택을 받을 것입니다.

항균제 분야에서 확고한 입지를 구축한 제약회사는 글락소스미스클라인, 아스트라제네카, 머크앤컴퍼니 세 곳뿐입니다. 더욱이 새로운 항균제를 개발하고 세균을 효과적으로 표적화할 수 있는 독특한 분자를 찾아내는 것은 결코 쉬운 일이 아닙니다. 대형 제약회사들과 과거 업계를 선도했던 기업들은 실패 위험이 높고 연구 개발 비용이 막대하다는 이유로 항균 연구 센터를 폐쇄하고 있습니다.
이러한 상황에서 미국 식품의약국(FDA)과 미국 감염병학회(IDSA)와 같은 기관들은 기업들이 항균 연구 개발에 다시 투자하도록 유도하기 위한 여러 프로그램을 시행하고 있습니다. 최근 제정된 GAIN(Generating Antibiotic Incentives Now) 법안은 보다 효율적인 임상 시험을 촉진하고 시장 진입 장벽을 낮추는 데 기여할 것으로 기대됩니다.

또한, 유럽의 혁신 의약품 이니셔티브(IMI)에서 시작한 두 가지 프로젝트인 유럽 내 세균 내성 퇴치(COMBACTE)와 TRANSLOCATION(세균 세포벽 투과성의 분자적 기초)은 항생제 내성 퇴치를 위해 산업계, 생명공학 기업, 학계와의 전례 없는 협력을 보여줍니다.
엄격한 약가 책정은 세계 항균제 시장의 성장을 저해하고 있습니다.
약가 책정은 다양한 이해관계자가 관련된 복잡한 과정이며, 비용 효율성에 큰 영향을 미칩니다. 가치 기반 가격 책정은 비용 효율적인 약가를 결정하는 방법입니다. 가치 기반 가격 책정이 새로운 항균제 가격에 어떤 영향을 미칠지는 현재로서는 불분명하지만, 중요한 요소는 가치의 정의입니다. 가치는 환자 건강에 미치는 영향뿐만 아니라 더 넓은 사회적 영향, 질병의 건강 영향과 같은 다른 요소도 포함할 수 있습니다.
제약 회사들은 항균제 개발에 투자하는 것을 꺼려 왔습니다. 항균제의 짧은 사용 기간과 저렴한 제네릭 의약품과의 치열한 경쟁으로 인해 신약 매출은 낮을 것으로 예상되었습니다. 최근 몇 년 동안 새로운 항균제 개발의 어려움과 기존 약물에 대한 내성 증가로 인해 감염 치료 선택지가 제한되었습니다.
항균제 시장 세분화 분석
세계 항균제 시장은 작용 유형, 약물 유형, 투여 경로, 약물 작용 기전, 유통 채널 및 지역별로 세분화됩니다.
베타-락탐 계열 항생제는 예측 기간 동안 시장에서 지배적인 위치를 차지할 것으로 예상됩니다.
베타-락탐 계열 항생제는 2022년 항균제 시장의 약 40.3%를 차지하며 가장 높은 시장 점유율을 기록했습니다. 이는 베타-락탐이 현재 항균 치료에 가장 많이 처방되는 항생제 계열 중 하나이기 때문입니다. 베타-락탐은 세포벽 형성 과정에서 교차 결합에 필요한 PBPs(단백질 결합 단백질)를 차단하여 세균의 성장을 억제합니다.

또한, 최근 FDA 승인 사례와 유망한 파이프라인을 보유한 제약 회사들이 향후 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2023년 1월 30일 인도 제약 회사인 알켐(Alkem)은 세프타지딤과 아비박탐의 새로운 복합제인 지다비(Zidavi)를 출시했습니다. 이 약은 미국 감염병학회(IDSA)와 인도 의학연구위원회(ICMR)에서 OXA-48 유사형 및 KPC(Klebsiella Pneumoniae Carbapenemase) 생성 카바페넴 내성 장내세균(CRE)에 의한 신우신염 및 기타 CRE 감염 치료에 권장되는 약물입니다.

항균제 시장 지역별 분포
북미는 전 세계 항균제 시장에서 지배적인 위치를 차지하고 있습니다.
북미는 항생제 내성 증가, 정부 정책, 그리고 지역별 FDA 승인 증가에 힘입어 예측 기간 동안 전체 시장 점유율의 약 36%를 차지할 것으로 예상됩니다.

예를 들어, 2023년 1월, Juno Pharmaceuticals Canada는 캐나다 보건부로부터 아목시실린 경구 현탁액 분말 수입 승인을 받았습니다. 이 승인은 현재 전국적으로 심각한 항생제 부족 현상을 완화하는 데 도움이 될 것입니다. 미국과 캐나다는 현재 항생제 부족 사태를 겪고 있습니다. 아목시실린 경구 현탁액은 특정 세균 감염 치료를 위해 어린이에게 가장 흔하게 처방되는 항생제 중 하나입니다.

항균제 기업 및 경쟁 환경
시장의 주요 글로벌 업체로는 Pfizer Inc., Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Shionogi & Co., Ltd., Eli Lilly and Company, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Novartis AG, Johnson & Johnson, AbbVie Inc., F. Hoffmann-La Roche AG, Melinta Therapeutics, Otsuka Pharmaceutical Co., Ltd., Insmed, Inc., Basilea Pharmaceutica, R-Pharm, Merck & Co., Inc., Venatorx Pharmaceuticals 등이 있습니다.
COVID-19가 항균제 시장에 미치는 영향
러시아-우크라이나 분쟁 분석
러시아의 우크라이나 침공은 심각한 인도주의적 위기를 초래했습니다. 민간인 전투원들은 심각한 부상을 입어 위독한 건강 문제를 겪고 있습니다. 항생제에 대한 무제한 접근과 러시아의 적대감은 광범위한 구매와 부적절한 사용으로 이어질 것입니다. 러시아와의 긴장이 항생제 내성(AMR)을 악화시키는 것을 막기 위해 긴급한 공중 보건 메시지를 전달해야 합니다.
작용 유형별
• 정균 작용
• 살균 작용
약물 유형별
• 베타락탐계
• 아미노글리코시드계
• 마크로라이드계
• 퀴놀론계
• 테트라사이클린계
• 설폰아미드계
• 기타
투여 경로별
• 경구 투여
• 주사 투여
• 기타
약물 작용 기전별
• 세포벽 합성 억제
• 단백질 합성 억제
• 세포막 변형
• 핵산 합성 억제
• 항대사 작용
유통 채널별
• 일반 약국
• 병원 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
• 아시아 태평양 지역 (기타)
• 중동 및 아프리카
주요 개발 사항
• 2022년 9월 22일, GSK plc와 Spero Therapeutics, Inc.는 Spero가 개발 중인 후기 임상 단계 항생제인 테비페넴 피복실 하이드로브로마이드(테비페넴 HBr)에 대한 독점 라이선스 계약을 체결했습니다. 테비페넴 HBr은 특정 세균에 의한 신우신염을 포함한 복합 요로 감염(cUTI) 치료에 잠재적으로 사용될 수 있는 최초의 경구용 카바페넴 항생제입니다.

• 2023년 2월 2일, Shionogi & Co.와 유럽 자회사인 Shionogi B.V.는 혁신적인 항생제인 FETCROJA(세피데로콜)가 치료 옵션이 제한적인 성인(18세 이상)의 호기성 그람 음성 세균 감염 치료를 위해 덴마크에서 출시되었다고 발표했습니다. 이번 덴마크 출시는 항생제 내성 감염이 증가하는 추세 속에서 유럽 전역에 세피데로콜 접근성을 신속하게 확대하는 데 중요한 단계입니다.

• 2022년 2월 22일, 시스테마 그룹(Sistema Group) 계열사인 비노팜 그룹(Binnopharm Group)은 러시아, 우즈베키스탄, 벨라루스에서 닥터 레디스 래버러토리스(Dr. Reddy's Laboratories)의 항균제 브랜드인 시프로렛(Ciprolet)과 레볼렛(Levolet)을 인수했습니다.
보고서 구매 이유:

• 작용 유형, 약물 유형, 투여 경로, 약효 기전, 유통 채널, 지역별 글로벌 항균제 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 항균제 시장 수준의 다양한 데이터가 담긴 엑셀 파일 제공.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서 제공.

• 주요 기업의 핵심 제품 정보를 담은 엑셀 파일 제공.

글로벌 항균제 시장 보고서는 약 77개의 표, 76개의 그림, 195페이지 분량으로 구성됩니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Antibacterial Drugs Market Overview
The global antibacterial drugs market reached USD 43,857.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 63,326.8 million by 2030. The global antibacterial drugs market is expected to exhibit a CAGR of 4.8% during the forecast period (2023-2030).
Recently marketed antimicrobial agents and waiting for FDA approval is one of the key trends in the global antibacterial drugs market. Many new antimicrobial agents with new targets have been marketed recently, while some of them are waiting for FDA approval. Some of them include macrocyclic antibiotics, newer cephalosporins, newer glycopeptides, newer carbapenems, pleuromutilin, and and among others.
Antibacterial drugs, usually known as antibiotics, are a type of medication used for bacterial infections. Antibiotics target certain bacteria or bacterial activities, such as cell wall or protein synthesis. The precise treatment and dosage will depend on the kind and severity of the disease. Antibacterial drugs can be delivered orally, topically, and intravenously among others.
Furthermore, rising incidence of chronic diseases, rising clinical trials, increasing FDA approvals, and growing research in antibacterial drugs are the factors that are expected to drive the market growth over the forecast period.
Antibacterial Drugs Market Dynamics and Trends
The rising number of market developments is boosting the global antibacterial drugs market growth.
The growing threat posed by multidrug-resistant gram-negative organisms (MDR-GNBs) is increasing the urgency with which antibacterial medications are being developed worldwide. Pharmaceutical producers will benefit from upcoming regulatory improvements that will reduce R&D costs and incentivize novel medication identification.
The only three established pharmaceutical companies in the antibacterial medicine space are GlaxoSmithKline, AstraZeneca, and Merck & Co. Moreover, it isn't easy to discover new antibacterial medications and uncover unique molecules that can successfully target germs. Big pharma corporations and formerly leaders are closing down their antimicrobial research centers due to the high risk of failure and costly R&D costs.
As a result, organizations such as the Food and Drug Administration (FDA) and the Infectious Diseases Society of America are launching several programs to entice corporations to return to antibacterial R&D. The recently enacted Generating Antibiotic Incentives Now (GAIN) Act is expected to promote more efficient clinical trials and lower market entry barriers.
Furthermore, Combating Bacterial Resistance in Europe (COMBACTE) and TRANSLOCATION (molecular basis of bacterial cell wall permeability) are two projects launched by the Innovative Medicines Initiative (IMI) in Europe that demonstrate an unprecedented collaboration with industry, biotech organizations, and academia to combat antibiotic resistance.
Stringent pricing of drugs is hampering the growth of the global antibacterial drugs market.
Drug pricing is a complicated process, involving different stakeholders, and has a large influence on cost-effectiveness. Value-based pricing is a method to determine the price of a drug at which it can be cost-effective. It is currently unclear what the influence of value-based pricing will be on the prices of new antibacterial agents, but an important factor will be the definition of value, which as well as the impact of the drug on patient health might also include other factors such as wider social impact and the health impact of the disease.
Pharmaceutical companies were reluctant to invest in the development of antibacterial agents; the revenues of the new drugs were expected to be low, because of the short use of antibacterial drugs and the high competition with many cheap generic drugs. The lack of new antibacterial agents and the growing resistance to the available drugs have limited the treatment options for infection in recent years.
Antibacterial Drugs Market Segment Analysis
The global antibacterial drugs market is segmented based on the action type, drug type, route of administration, drug mechanism,distribution channel and region.
The beta-lactams segment is expected to hold a dominant position in the market over the forecast period.
Beta-lactams segment accounted for the highest market stake accounting for approximately 40.3% of the antibacterial drugs market in 2022. The segment benefits because β-Lactams are one of the most often prescribed antibiotic classes for antibacterial treatment today. They restrict bacterial growth by blocking PBPs, which are required for cross-linking during cell wall formation.
Moreover, there are recent FDA approvals and pharmaceutical companies that have promising pipelines that are expected to drive the market growth over the forecast period. For instance, on January 30, 2023, Alkem, an India-based company, launched Zidavi, a novel combination of ceftazidime and avibactam. It is recommended by the IDSA and ICMR as a preferred treatment against OXA-48-like and Klebsiella Pneumoniae Carbapenemase (KPC)-producing Carbapenem-Resistant Enterobacteriaceae (CRE) for pyelonephritis and other CRE infections caused by KPC and OXA-48.

Antibacterial Drugs Market Geographical Penetration
North America holds a dominant position in the global antibacterial drugs market.
North America is estimated to hold around 36% of the total market share throughout the forecast period, owing to the increased antibiotic resistance, government initiatives, and increased regional FDA approvals.
For instance, in January 2023, Juno Pharmaceuticals Canada received approval from Health Canada to import Amoxicillin powder for oral suspension Amoxicillin. This approval helps to relieve the current nationwide shortage of critical antibiotic products. The U.S. and Canada are experiencing a nationwide shortage of antibiotics. Amoxicillin oral suspension is one of the most commonly prescribed antibiotics for children to treat particular bacterial infections.

Antibacterial Drugs Companies and Competitive Landscape
The major global players in the market include Pfizer Inc., Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Shionogi & Co., Ltd., Eli Lilly and Company, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Novartis AG, Johnson & Johnson, AbbVie Inc., F. Hoffmann-La Roche AG, Melinta Therapeutics, Otsuka Pharmaceutical Co., Ltd., Insmed, Inc., Basilea Pharmaceutica, R-Pharm, Merck & Co., Inc., and Venatorx Pharmaceuticals among others.
COVID-19 Impact on Antibacterial Drugs Market
Russia Ukraine Conflict Analysis
The invasion of Ukraine by Russia has caused a severe humanitarian crisis. Civilian combatants have sustained severe wounds, leading to critical health issues. Unrestricted access to antimicrobials and Russian enmity will lead to widespread purchase and inappropriate usage. Urgent public health messages must be distributed to stop Russian tensions from worsening AntiMicrobial Resistance (AMR).
By Action Type
• Bacteriostatic
• Bactericidal
By Drug Type
• Beta-lactams
• Aminoglycosides
• Macrolides
• Quinolones
• Tetracyclines
• Sulfonamide
• Others
By Route of Administration
• Oral
• Parenteral
• Others
By Drug Mechanism
• Inhibition of Cell Wall Synthesis
• Inhibition of Protein Synthesis
• Alteration of Cell Membranes
• Inhibition of Nucleic Acid Synthesis
• Antimetabolite Activity
By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
By Region
• North America
o The U.S.
o Canada
o Mexico
• Europe
o Germany
o The U.K.
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On September 22, 2022, GSK plc and Spero Therapeutics, Inc. entered into an exclusive license agreement for tebipenem pivoxil hydrobromide (tebipenem HBr), a late-stage antibiotic being developed by Spero, as the first oral carbapenem antibiotic to potentially treat complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain bacteria.
• On February 2, 2023, Shionogi & Co. and its European subsidiary, Shionogi B.V., announced that its innovative antibiotic, FETCROJA (cefiderocol), is now available in Denmark for treating infections due to aerobic Gram-negative bacteria in adults (18 years or older) with limited treatment options. This launch in Denmark is an important step in rapidly expanding access to cefiderocol across Europe, with an increasing trend in antibiotic-resistant infections.
• On February 22, 2022, Sistema Group company, Binnopharm Group, acquired Dr. Reddy's Laboratories' anti-bacterial medicines underneath the Ciprolet and Levolet brands in Russia, Uzbekistan, and Belarus.
Why Purchase the Report?
• To visualize the global antibacterial drugs market segmentation based on the action type, drug type, route of administration, drug mechanism, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of antibacterial drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global antibacterial drugs market report would provide approximately 77 tables, 76 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Action Type
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Drug Mechanism
3.5. Snippet by Distribution Channel
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. High prevalence of bacterial diseases such as tuberculosis, chlamydia, and vaginal vaginosis
4.1.1.2. Rising development and commercialization of antibacterial drugs
4.1.2. Restraints
4.1.2.1. Stringent pricing of drugs
4.1.3. Opportunity
4.1.3.1. Increasing number of clinical trials
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. By Action Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
8.1.2. Market Attractiveness Index, By Action Type
8.2. Bacteriostatic*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Bactericidal
9. By Drug Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.1.2. Market Attractiveness Index, By Drug Type
9.2. Beta-lactams*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Aminoglycosides
9.4. Macrolides
9.5. Quinolones
9.6. Tetracyclines
9.7. Sulfonamide
9.8. Others
10. By Route of Administration
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.1.2. Market Attractiveness Index, By Route of Administration
10.2. Oral*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Parenteral
10.4. Others
11. By Drug Mechanism
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
11.1.2. Market Attractiveness Index, By Drug Mechanism
11.2. Inhibition of Cell Wall Synthesis*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Inhibition of Protein Synthesis
11.4. Alteration of Cell Membranes
11.5. Inhibition of Nucleic Acid Synthesis
11.6. Antimetabolite Activity
12. By Distribution Channel
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.1.2. Market Attractiveness Index, By End User
12.2. Retail Pharmacies*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Hospital Pharmacies
12.4. Online Pharmacies
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.8.1. The U.S.
13.2.8.2. Canada
13.2.8.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.8.1. Germany
13.3.8.2. The U.K.
13.3.8.3. France
13.3.8.4. Italy
13.3.8.5. Spain
13.3.8.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.8.1. Brazil
13.4.8.2. Argentina
13.4.8.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.8.1. China
13.5.8.2. India
13.5.8.3. Japan
13.5.8.4. Australia
13.5.8.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
13.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Market Share Analysis
14.3. Mergers and Acquisitions Analysis
15. Company Profiles
15.1. Pfizer Inc.*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Sanofi S.A.
15.3. Bayer AG
15.4. Teva Pharmaceutical Industries Ltd.
15.5. AstraZeneca Plc.
15.6. Novartis AG
15.7. Bristol Myers Squibb Company
15.8. GlaxoSmithKline Plc
15.9. Eli Lilly and Company
15.10. Allecra Therapeutics GmbH(*LIST NOT EXHAUSTIVE)
16. Appendix
16.1. About Us and Services
16.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4. Key Developments, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca Plc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline Plc, Eli Lilly and Company

표 목록 (Tables)

List of Tables

Table 1 Global Antibacterial Drugs Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Antibacterial Drugs Market Value, By Spectrum of Activity, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Antibacterial Drugs Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Antibacterial Drugs Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Antibacterial Drugs Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Antibacterial Drugs Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 7 Global Antibacterial Drugs Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Billion)

Table 8 Global Antibacterial Drugs Market Value, By Drug Type, 2022-2033 (US$ Billion)

Table 9 Global Antibacterial Drugs Market Value, By Spectrum of Activity, 2025, 2029 & 2033 (US$ Billion)

Table 10 Global Antibacterial Drugs Market Value, By Spectrum of Activity, 2022-2033 (US$ Billion)

Table 11 Global Antibacterial Drugs Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)

Table 12 Global Antibacterial Drugs Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 13 Global Antibacterial Drugs Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)

Table 14 Global Antibacterial Drugs Market Value, By Indication, 2022-2033 (US$ Billion)

Table 15 Global Antibacterial Drugs Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 16 Global Antibacterial Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 17 Global Antibacterial Drugs Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 18 Global Antibacterial Drugs Market Value, By Region, 2022-2033 (US$ Billion)

Table 19 North America Antibacterial Drugs Market Value, By Drug Type, 2022-2033 (US$ Billion)

Table 20 North America Antibacterial Drugs Market Value, By Spectrum of Activity, 2022-2033 (US$ Billion)

Table 21 North America Antibacterial Drugs Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 22 North America Antibacterial Drugs Market Value, By Indication, 2022-2033 (US$ Billion)

Table 23 North America Antibacterial Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 24 North America Antibacterial Drugs Market Value, By Country, 2022-2033 (US$ Billion)

Table 25 Europe Antibacterial Drugs Market Value, By Drug Type, 2022-2033 (US$ Billion)

Table 26 Europe Antibacterial Drugs Market Value, By Spectrum of Activity, 2022-2033 (US$ Billion)

Table 27 Europe Antibacterial Drugs Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 28 Europe Antibacterial Drugs Market Value, By Indication, 2022-2033 (US$ Billion)

Table 29 Europe Antibacterial Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 30 Europe Antibacterial Drugs Market Value, By Country, 2022-2033 (US$ Billion)

Table 31 Asia-Pacific Antibacterial Drugs Market Value, By Drug Type, 2022-2033 (US$ Billion)

Table 32 Asia-Pacific Antibacterial Drugs Market Value, By Spectrum of Activity, 2022-2033 (US$ Billion)

Table 33 Asia-Pacific Antibacterial Drugs Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 34 Asia-Pacific Antibacterial Drugs Market Value, By Indication, 2022-2033 (US$ Billion)

Table 35 Asia-Pacific Antibacterial Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 36 Asia-Pacific Antibacterial Drugs Market Value, By Country, 2022-2033 (US$ Billion)

Table 37 South America Antibacterial Drugs Market Value, By Drug Type, 2022-2033 (US$ Billion)

Table 38 South America Antibacterial Drugs Market Value, By Spectrum of Activity, 2022-2033 (US$ Billion)

Table 39 South America Antibacterial Drugs Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 40 South America Antibacterial Drugs Market Value, By Indication, 2022-2033 (US$ Billion)

Table 41 South America Antibacterial Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 42 South America Antibacterial Drugs Market Value, By Country, 2022-2033 (US$ Billion)

Table 43 Middle East and Africa Antibacterial Drugs Market Value, By Drug Type, 2022-2033 (US$ Billion)

Table 44 Middle East and Africa Antibacterial Drugs Market Value, By Spectrum of Activity, 2022-2033 (US$ Billion)

Table 45 Middle East and Africa Antibacterial Drugs Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 46 Middle East and Africa Antibacterial Drugs Market Value, By Indication, 2022-2033 (US$ Billion)

Table 47 Middle East and Africa Antibacterial Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 48 Middle East and Africa Antibacterial Drugs Market Value, By Country, 2022-2033 (US$ Billion)

Table 49 Pfizer Inc.: Overview

Table 50 Pfizer Inc.: Product Portfolio

Table 51 Pfizer Inc.: Key Developments

Table 52 Merck & Co., Inc.: Overview

Table 53 Merck & Co., Inc.: Product Portfolio

Table 54 Merck & Co., Inc.: Key Developments

Table 55 Sanofi: Overview

Table 56 Sanofi: Product Portfolio

Table 57 Sanofi: Key Developments

Table 58 GSK plc: Overview

Table 59 GSK plc: Product Portfolio

Table 60 GSK plc: Key Developments

Table 61 AstraZeneca: Overview

Table 62 AstraZeneca: Product Portfolio

Table 63 AstraZeneca: Key Developments

Table 64 Teva Pharmaceuticals USA, Inc.: Overview

Table 65 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table 66 Teva Pharmaceuticals USA, Inc.: Key Developments

Table 67 Bristol-Myers Squibb Company: Overview

Table 68 Bristol-Myers Squibb Company: Product Portfolio

Table 69 Bristol-Myers Squibb Company: Key Developments

Table 70 Paratek Pharmaceuticals, Inc.: Overview

Table 71 Paratek Pharmaceuticals, Inc.: Product Portfolio

Table 72 Paratek Pharmaceuticals, Inc.: Key Developments

Table 73 Cipla Therapeutics: Overview

Table 74 Cipla Therapeutics: Product Portfolio

Table 75 Cipla Therapeutics: Key Developments

Table 76 Innoviva Specialty Therapeutics: Overview

Table 77 Innoviva Specialty Therapeutics: Product Portfolio

Table 78 Innoviva Specialty Therapeutics: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Antibacterial Drugs Market Share, By Drug Type, 2024 & 2033 (%)

Figure 3 Global Antibacterial Drugs Market Share, By Spectrum of Activity, 2024 & 2033 (%)

Figure 4 Global Antibacterial Drugs Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 5 Global Antibacterial Drugs Market Share, By Indication, 2024 & 2033 (%)

Figure 6 Global Antibacterial Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 7 Global Antibacterial Drugs Market Share, By Region, 2024 & 2033 (%)

Figure 8 Global Antibacterial Drugs Market Y-o-Y Growth, By Drug Type, 2023-2033 (%)

Figure 9 Beta-lactams Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 10 Aminoglycosides Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 11 Macrolides Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 12 Quinolones Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 13 Tetracyclines Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 14 Sulfonamides Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 15 Others Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 16 Global Antibacterial Drugs Market Y-o-Y Growth, By Spectrum of Activity, 2023-2033 (%)

Figure 17 Broad-Spectrum Antibiotics Spectrum of Activity in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 18 Narrow-Spectrum Antibiotics Spectrum of Activity in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 19 Global Antibacterial Drugs Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)

Figure 20 Oral Route of Administration in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 21 Parenteral Route of Administration in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 22 Topical Route of Administration in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 23 Global Antibacterial Drugs Market Y-o-Y Growth, By Indication, 2023-2033 (%)

Figure 24 Respiratory Tract Infections Indication in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 25 Urinary Tract Infections Indication in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 26 Skin and Soft Tissue Infections Indication in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 27 Gastrointestinal Infections Indication in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 28 Sexually Transmitted Infections Indication in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 29 Sepsis and Bloodstream Infections Indication in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 30 Ear, Nose & Throat Infections Indication in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 31 Hospital-acquired Infections (HAIs) Indication in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 32 Others Indication in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 33 Global Antibacterial Drugs Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 34 Hospital Pharmacies Distribution Channel in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 35 Retail Pharmacies Distribution Channel in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 36 Online Pharmacies Distribution Channel in Global Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 37 Global Antibacterial Drugs Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 38 North America Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 39 North America Antibacterial Drugs Market Share, By Drug Type, 2024 & 2033 (%)

Figure 40 North America Antibacterial Drugs Market Share, By Spectrum of Activity, 2024 & 2033 (%)

Figure 41 North America Antibacterial Drugs Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 42 North America Antibacterial Drugs Market Share, By Indication, 2024 & 2033 (%)

Figure 43 North America Antibacterial Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 44 North America Antibacterial Drugs Market Share, By Country, 2024 & 2033 (%)

Figure 45 Europe Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 46 Europe Antibacterial Drugs Market Share, By Drug Type, 2024 & 2033 (%)

Figure 47 Europe Antibacterial Drugs Market Share, By Spectrum of Activity, 2024 & 2033 (%)

Figure 48 Europe Antibacterial Drugs Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 49 Europe Antibacterial Drugs Market Share, By Indication, 2024 & 2033 (%)

Figure 50 Europe Antibacterial Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 51 Europe Antibacterial Drugs Market Share, By Country, 2024 & 2033 (%)

Figure 52 Asia-Pacific Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 53 Asia-Pacific Antibacterial Drugs Market Share, By Drug Type, 2024 & 2033 (%)

Figure 54 Asia-Pacific Antibacterial Drugs Market Share, By Spectrum of Activity, 2024 & 2033 (%)

Figure 55 Asia-Pacific Antibacterial Drugs Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 56 Asia-Pacific Antibacterial Drugs Market Share, By Indication, 2024 & 2033 (%)

Figure 57 Asia-Pacific Antibacterial Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 58 Asia-Pacific Antibacterial Drugs Market Share, By Country, 2024 & 2033 (%)

Figure 59 South America Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 60 South America Antibacterial Drugs Market Share, By Drug Type, 2024 & 2033 (%)

Figure 61 South America Antibacterial Drugs Market Share, By Spectrum of Activity, 2024 & 2033 (%)

Figure 62 South America Antibacterial Drugs Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 63 South America Antibacterial Drugs Market Share, By Indication, 2024 & 2033 (%)

Figure 64 South America Antibacterial Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 65 South America Antibacterial Drugs Market Share, By Country, 2024 & 2033 (%)

Figure 66 Middle East and Africa Antibacterial Drugs Market Value, 2022-2033 (US$ Billion)

Figure 67 Middle East and Africa Antibacterial Drugs Market Share, By Drug Type, 2024 & 2033 (%)

Figure 68 Middle East and Africa Antibacterial Drugs Market Share, By Spectrum of Activity, 2024 & 2033 (%)

Figure 69 Middle East and Africa Antibacterial Drugs Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 70 Middle East and Africa Antibacterial Drugs Market Share, By Indication, 2024 & 2033 (%)

Figure 71 Middle East and Africa Antibacterial Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 72 Pfizer Inc.: Financials

Figure 73 Merck & Co., Inc.: Financials

Figure 74 Sanofi: Financials

Figure 75 GSK plc: Financials

Figure 76 AstraZeneca: Financials

Figure 77 Teva Pharmaceuticals USA, Inc.: Financials

Figure 78 Bristol-Myers Squibb Company: Financials

Figure 79 Paratek Pharmaceuticals, Inc.: Financials

Figure 80 Cipla Therapeutics: Financials

Figure 81 Innoviva Specialty Therapeutics: Financials